NASDAQ$NKGN

Nkgen Biotech Inc · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

NKGN Q4 2023 — extraction skipped

Nkgen Biotech Inc filed Form 10-K/A (accession 0001213900-24-037289) for Q4 2023, but headline financial numerics could not be extracted automatically: no headline numerics found by parser nor by Financial Datasets fallback. The row is marked as AI-processed so the queue advances; numerics will be filled by Financial Datasets on its next pass.

  • Form 10-K/A filed; press release body not parseable here.
  • Reason: no headline numerics found by parser nor by Financial Datasets fallback.
  • Numerics rely on the Financial Datasets fallback.

Headline financials

Total Revenue

$0.00

No prior period
EPS (adj)

-$1.68

Previous: -$0.14-1100.0%
Capital Expenditures

-$18K

Previous: -$8K-125.0%
Net Income

-$33.6M

Previous: -$3.02M-1011.5%
Operating Income

-$9.43M

Previous: -$635K-1385.1%
Gross Profit

-$300K

Previous: -$15K-1900.0%
R&D Expense

$3.79M

No prior period
Stock-Based Comp

$928K

Previous: $15K+6086.7%

Revenue & EPS history

Nkgen Biotech · Revenue · Quarterly

$0

Q4 2023

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 17 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

+6.0%

Avg return

Earnings day

-0.7%

Avg return

5 days after

+2.7%

Avg return

30 days after

41%

7 / 17 earnings

Positive

+57.1%

Q1 2024

Best reaction

-16.9%

Q4 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025+0.0%+0.0%+0.0%
Q1 2025+0.0%+0.0%+0.0%
Q2 2025+0.0%+0.0%+85.0%
Q4 2024+21.4%+0.0%-5.0%
Q3 2024+36.1%+4.7%-5.8%
Q2 2024-0.8%-37.1%-64.1%
Q1 2024+57.1%+26.8%+6.3%
Q4 2023-16.9%-10.8%-8.9%
Q3 2023+5.1%+2.6%+37.9%
Q2 2023+0.3%+0.8%-2.9%
Q1 2023+0.3%-0.3%+0.0%
Q4 2022+0.3%-0.3%+0.0%
Q3 2022-0.3%+0.3%+0.5%
Q2 2022+0.0%+0.0%-0.1%
Q1 2022+0.0%+0.3%+0.7%
Q4 2021+0.0%+0.3%+0.7%
Q3 2021+0.0%+0.2%+1.0%
Q1 2021

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro